INSIGHTS ON DRUG DISCOVERY

• Integrated Drug Discovery: Hit To PCC In 16 Months

  Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.

• ADC Development Grows More Complex — SPR Insights Bring Clarity

  Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

• Mammalian Cell Line Development

  Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.

• WuXia293Stable: Express What CHO Can't

  Discover a modern 293‑based expression system built for higher purity, controlled glycosylation, and improved activity, offering a new option for teams developing complex or next‑generation biologics.

• What Matters More In DNA-Encoded Libraries?

  3/16/2026

  DELs can screen billions of compounds, but library quality determines meaningful results. See how thoughtful design shapes early decisions that influence which drug candidates move forward.

• Translating Massive Data Into Therapeutic Momentum

  3/13/2026

  New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.

• ADCs: Overcoming Analytical Challenges In Next-Gen Cancer Therapies

  2/24/2026

  Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment. But with innovation comes complexity. 

• What FDA CRLs Reveal About E&L

  2/18/2026

  FDA feedback shows E&L gaps still delay approvals. This preview flags common issues — from unknown compounds to weak tox data — and offers ways to strengthen E&L approaches and cut regulatory risk.

• From Promise To Patients: Smarter Pathways To Scale In Cell And Gene Therapy Manufacturing

  2/12/2026

  As the field evolves, the strategies developers choose may prove just as influential as the therapies themselves in determining how quickly innovation reaches patients.